|
US2019267123A1
|
|
Managing healthcare services
|
|
US2018044414A1
|
|
Methods and compositions for treatment of skin disorders
|
|
US2016342747A1
|
|
Systems and methods for tracking trends in patient data
|
|
US2016280776A1
|
|
Uses and Compositions for Treatment of Juvenile Rheumatoid Arthritis
|
|
AU2015227439A1
|
|
Wearable automatic injection device for controlled delivery of therapeutic agents
|
|
AU2015215873A1
|
|
Treatment of TNFalpha related disorders
|
|
US2016200809A1
|
|
Uses and Compositions for Treatment of Psoriasis
|
|
WO2015109167A1
|
|
Managing healthcare services
|
|
AU2014202693A1
|
|
Human antibodies that bind human TNFalpha
|
|
CN105121470A
|
|
Anti-cd25 antibodies and their uses
|
|
AU2013257402A1
|
|
Human antibodies that bind human TNFalpha
|
|
NZ631746A
|
|
Characterization and/or detection of structural characteristics associated with syringes and/or automatic injection devices based on acoustics
|
|
EP2907061A1
|
|
Managing healthcare services
|
|
AU2013204406A1
|
|
Automatic injection device
|
|
AU2013204472A1
|
|
Multiple-variable dose regimen for treating TNFalpha-related disorders
|
|
AU2013204238A1
|
|
Stable high protein concentration formulations of human anti-TNF-alpha-antibodies
|
|
AU2013204359A1
|
|
Methods of administering anti-TNFalpha antibodies
|
|
AU2013204044A1
|
|
Protein formulations and methods of making same
|
|
AU2013203420A1
|
|
Human antibodies that bind human TNFalpha
|
|
AU2013202811A1
|
|
Antibody purification
|
